Across TCGA pan-cancer cohorts, MIR610 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated MIR610 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher MIR610 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR610 expression acts as an unfavorable survival marker, although some lineages such as OV and BRCA show a favorable association.
MESO, HNSC, and KIRP are the cancer types where MIR610 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.